The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.
Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD.
The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.
Age ≥18 years;
Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria;
Patient with any nodal mass ≥ than 10 cm can be included
No previous treatment for Hodgkin lymphoma;
Stage II B- III- IV
Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype
Active HBV and HCV infection
HIV seropositivity